Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. by Emens, L.A. & Romero, P.
EDITORIAL Open Access
Introducing the clinical trials monitor: a
new section of the journal for
immunotherapy of cancer
Leisha A. Emens1* and Pedro Romero2
Background
Since its inception, the Journal for Immunotherapy of
Cancer (JITC) has focused on all aspects of tumor im-
munology and cancer immunotherapy from bench to
bedside. Clinical advances in immuno-oncology are ac-
celerating, with an increasing number of approved
drugs that specifically target the immune system to
treat cancer. The success of these agents in the clinic
has given rise to a rapidly expanding portfolio of trials
testing cancer immunotherapies in patients with a var-
iety of cancer types. Given the explosion of interest and
clinical activity in cancer immunotherapy, we are
pleased to launch a new section of JITC, the Clinical
Trials Monitor, edited by Leisha A. Emens, MD PhD, of
the Johns Hopkins University.
Introducing the section
The Clinical Trials Monitor section aims to publish
and provide perspectives on late stage clinical trial re-
sults, highlight immuno-oncology trials in progress,
and summarize important new regulatory approvals in
cancer immunotherapy. The section also aims to address
trial design and analysis considerations that may be unique
to cancer immunotherapy, and to provide guidance for
implementing and managing the use of cancer im-
munotherapies in the clinic. The section will disseminate
clinically oriented information and perspectives in the
following formats:
Clinical trial reports
This feature will include Phase 2 or 3 clinical trials with
primary clinical endpoints, studies that define biomarkers
of therapeutic response, primary resistance to
immunotherapy, and immune escape, and trials that define
the patient experience (quality of life) with cancer
immunotherapies.
Into the clinic
This feature will review newly approved immunotherapies,
highlighting the drug development process for the agent
and indication, including any important biomarkers. It will
also provide guidance about how the newly approved drug
fits into the standard of care as it enters the clinic. These
pieces will be written by leading immunotherapy experts
in disease-specific areas, and should help inform the de-
velopment of clinical practice guidelines by SITC, NCCN,
and ASCO.
Regulatory approval summary
This feature will include approval summaries from regula-
tory agencies around the world as new immunotherapies
are approved for standard clinical use.
Cutting edge: Immunotherapy clinical trials in
progress
This feature will highlight clinical trials grouped by
modality, pathway, or disease subtype. These summaries
will include an introduction followed by clinical trials in
progress within the domain of focus. They will span early
first-in-man single agent (novel immune checkpoint targets
or innovative vaccine strategies) or important combination
strategies (IDO inhibition with vaccines or immune check-
point blockade), and later stage trials testing novel combi-
nations with more established immunotherapies (radiation
with immune checkpoint blockade).
Glimpse of the future: emerging immunotherapies
These pieces will succinctly highlight mechanistic principles
underlying emerging immunotherapeutic strategies and
technologies entering the clinic, providing a sound
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scientific foundation for trial design and evaluating the
preclinical and clinical literature.
Beyond the numbers
This educational feature puts cancer immunotherapy into
broad context. Subject matter may include a discussion
of statistical considerations and perspectives essential
for understanding results of pivotal clinical trials, clinical
trial design and data analysis issues particularly relevant to
cancer immunotherapy, and unresolved issues related to
reduction to practice (toxicity management or issues re-
lated to access to novel immunotherapies (adoptive T cell
therapy/CAR T cells).
Conclusions
The Clinical Trials Monitor section will serve as a valu-
able resource for researchers and clinicians. It will report
important new trial results, provide timely updates on
new drug approvals and important ongoing clinical
studies, and deliver key perspectives on clinical issues
and advances in the field relevant to the everyday use
of cancer immunotherapy in the clinic. A talented group
of Editorial Board members from around the world with
broad expertise in immuno-oncology will oversee the sec-
tion. We expect to adapt the section to meet the changing
needs of the field and the JITC readership, and we invite
your feedback. These are exciting times for cancer im-
munotherapy, and we at JITC share your interest and en-
thusiasm for using cancer immunotherapy to transform
cancer medicine and change the lives of cancer patients.
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